LUCIANA BERTOCCO DE PAIVA HADDAD

(Fonte: Lattes)
Índice h a partir de 2011
12
Lattes
ResearcherID
ORCID
Projetos de Pesquisa
Unidades Organizacionais
Instituto Central, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/37 - Laboratório de Transplante e Cirurgia de Fígado, Hospital das Clínicas, Faculdade de Medicina

Filtros

Limpar filtros

Configurações

Autor: HADDAD, Luciana ×

Resultados de Busca

Agora exibindo 1 - 10 de 24
  • conferenceObject
    The Influence of Antifungal Prophylaxis in Invasive Fungal Infections in Liver Transplantation
    (2015) SONG, Alice T. W.; ALMEIDA JUNIOR, Joao N.; MAU, Luciana B.; FREIRE, Maristela; PROENCA, Adriana; HADDAD, Luciana; D'ALBUQUERQUE, Luiz A. C.; ABDALA, Edson
  • article 22 Citação(ões) na Scopus
    Factors Associated with Mortality and Graft Failure in Liver Transplants: A Hierarchical Approach
    (2015) HADDAD, Luciana; CASSENOTE, Alex Jones Flores; ANDRAUS, Wellington; MARTINO, Rodrigo Bronze de; ORTEGA, Neli Regina de Siqueira; ABE, Jair Minoro; D'ALBUQUERQUE, Luiz Augusto Carneiro
    Background Liver transplantation has received increased attention in the medical field since the 1980s following the introduction of new immunosuppressants and improved surgical techniques. Currently, transplantation is the treatment of choice for patients with end-stage liver disease, and it has been expanded for other indications. Liver transplantation outcomes depend on donor factors, operating conditions, and the disease stage of the recipient. A retrospective cohort was studied to identify mortality and graft failure rates and their associated factors. All adult liver transplants performed in the state of Sao Paulo, Brazil, between 2006 and 2012 were studied. Methods and Findings A hierarchical Poisson multiple regression model was used to analyze factors related to mortality and graft failure in liver transplants. A total of 2,666 patients, 18 years or older, (1,482 males; 1,184 females) were investigated. Outcome variables included mortality and graft failure rates, which were grouped into a single binary variable called negative outcome rate. Additionally, donor clinical, laboratory, intensive care, and organ characteristics and recipient clinical data were analyzed. The mortality rate was 16.2 per 100 person-years (py) (95% CI: 15.1-17.3), and the graft failure rate was 1.8 per 100 py (95% CI: 1.5-2.2). Thus, the negative outcome rate was 18.0 per 100 py (95% CI: 16.9-19.2). The best risk model demonstrated that recipient creatinine >= 2.11 mg/dl [RR = 1.80 (95% CI: 1.56-2.08)], total bilirubin >= 2.11 mg/dl [RR = 1.48 (95% CI: 1.27-1.72)], Na+ >= 141.01 mg/dl [RR = 1.70 (95% CI: 1.47-1.97)], RNI >= 2.71 [RR = 1.64 (95% CI: 1.41-1.90)], body surface >= 1.98 [RR = 0.81 (95% CI: 0.68-0.97)] and donor age >= 54 years [RR = 1.28 (95% CI: 1.11-1.48)], male gender [RR = 1.19(95% CI: 1.03-1.37)], dobutamine use [RR = 0.54 (95% CI: 0.36-0.82)] and intubation >= 6 days [RR = 1.16 (95% CI: 1.10-1.34)] affected the negative outcome rate. Conclusions The current study confirms that both donor and recipient characteristics must be considered in post-transplant outcomes and prognostic scores. Our data demonstrated that recipient characteristics have a greater impact on post-transplant outcomes than donor characteristics. This new concept makes liver transplant teams to rethink about the limits in a MELD allocation system, with many teams competing with each other. The results suggest that although we have some concerns about the donors features, the recipient factors were heaviest predictors for bad outcomes.
  • conferenceObject
    Renal Insufficiency Leads To Increased Mortality in Post-Liver Transplantation.
    (2014) HADDAD, Luciana; DUCATTI, Liliana; MALBOUISSON, Luiz Marcelo; MACEDO, Etienne; OHNISHI, Luis; LIMA, Camila; ANDRAUS, Wellington; CARRILHO, Flair Jose; D'ALBUQUERQUE, Luiz Augusto Carneiro
  • conferenceObject
    The Shortage of Donor for Intestinal and Multivisceral Transplantation in Brazil.
    (2015) CALIL, Igor; LEITE, Andre Z.; ANDRADE, Guilherme; MALBOUISSON, Luis Marcelo; SALIBA, Gustavo; DUCATTI, Liliana; PINHEIRO, Rafael S.; ROCHA, Vinicius S.; BRONZE, Rodrigo M.; ANDRAUS, Wellington; SOLER, Wangles V.; HADDAD, Luciana; NACIF, Lucas S.; PANTANALI, Carlos; PECORA, Rafael A.; DAVID, Andre I.; GALVAO, Flavio H.; D'ALBUQUERQUE, Luiz Augusto C.
  • conferenceObject
    COVID-19 Infection in Liver Transplant Recipients: Results From a Brazillian Multicentric Historical Cohort
    (2022) BOIN, Ilka F. S. F.; RICCETTO, Eduardo; GENZINI, Tercio; MOREIRA, Lucio F. P.; STUCCHI, Raquel S. B.; SILVA, Renato F.; HADDAD, Luciana; ALMEIDA, Marcio D.; WATANABE, Andre; PEIXOTO, Gustavo S.; MELO, Claudio M. L.; TEFFILI, Nertan L.; HALPERN, Marcia; GODOY, Maira C.; MANCERO, Jorge M. P.; GARCIA, Jose Huygens P.; ATAIDE, Elaine C.
  • conferenceObject
    Impact of Donor Age and Time on Mechanical Ventilation on Outcomes of Liver Transplantation in Brazil
    (2014) HADDAD, Luciana; CASSENOTE, Alex; OLIVEIRA, Cristina C.; ANDRAUS, Wellington; D'ALBUQUERQUE, Luiz Augusto Carneiro
  • article 2 Citação(ões) na Scopus
    Adult -to -Adult Living Donor Liver Transplant: Hemodynamic Evaluation, and Selection
    (2020) NACIF, Lucas Souto; ZANINI, Leonardo Yuri; WAISBERG, Daniel Reis; SANTOS, Joao Paulo Costa dos; PEREIRA, Juliana Marquezi; PINHEIRO, Rafael Soares; ROCHA-SANTOS, Vinicius; MARTINO, Rodrigo Bronze; ARANTES, Rubens Macedo; DUCATTI, Liliana; HADDAD, Luciana; GALVAO, Flavio Henrique; ANDRAUS, Wellington; CARNEIRO-D'ALBUQUERQUE, Luiz
  • article 5 Citação(ões) na Scopus
    Intraoperative Temporary Portocaval Shunt in Liver Transplant
    (2020) NACIF, Lucas Souto; ZANINI, Leonardo Yuri; SANTOS, Joao Paulo Costa dos; PEREIRA, Juliana Marquezi; PINHEIRO, Rafael Soares; ROCHA-SANTOS, Vinicius; MARTINO, Rodrigo Bronze de; WAISBERG, Daniel Reis; ARANTES, Rubens Macedo; DUCATTI, Liliana; HADDAD, Luciana; GALVAO, Flavio Henrique; ANDRAUS, Wellington; CARNEIRO-D'ALBUQUERQUE, Luiz
  • article 0 Citação(ões) na Scopus
    Understanding the Elevated Lethality of COVID-19 in Liver Transplant Recipients: Does Immunosuppression Management Matter? Results from a Brazilian Multicentric Historical Cohort
    (2023) BOIN, Ilka Fsf; RICCETTO, Eduardo; GENZINI, Tercio; SANTOS, Regina Gomes; MOREIRA, Lucio Figueira Pacheco; PINTO, Laura Cristina Machado; GARCIA, Jose Huygens Parente; STUCCHI, Raquel Sb; PERALES, Simone Reges; ZANAGA, Leticia; SILVA, Renato Fereira Da; SILVA, Rita Cm Fereira Da; HADDAD, Luciana; D'ALBUQUERQUE, Luiz Ac; DEALMEIDA, Marcio Dias; WATANABE, Andre; PEIXOTO, Gustavo S.; MELO, Claudio Moura Lacerda De; BEZERRA, Renata Ferreira; TEFILLI, Nertan Luiz; HALPERN, Marcia; GODOY, Maira Silva; NOGARA, Marcelo; MANCERO, Jorge Marcelo Padilla; NOUJAIM, Huda Maria; RANGEL, Erika Bevilaqua; ATAIDE, Elaine Cristina
    Background. Infections by SARS-CoV-2 in liver transplant recipients (LT) patients are of particular concern, notably due to perceived added risks related to immunosuppression and comorbidity burden. Current literature on this topic often relies on small, non-standardized, and geographically limited studies. This manuscript describes COVID-19 presentations and causes for elevated mortality in a large cohort of LT recipients. Methods. This study was designed as a multicentric historical cohort, including LT recipient patients with COVID-19 in 25 study centers, with the primary endpoint being COVID-related death. We also collected demographic, clinical, and laboratory data regarding presentation and disease progression. Results. Two hundred and thirty-four cases were included. The study population was predominantly male and White and had a median age of 60 years. The median time from transplantation was 2.6 years (IQR 1-6). Most patients had at least one comorbidity (189, 80.8%). Patient age (P = .04), dyspnea (P < .001), intensive care unit admission (P < .001), and mechanical ventilation (P < .001) were associated with increased mortality. Modifications of immunosuppressive therapy (P < .001), specifically the suspension of tacrolimus, maintained significance in multi-variable analysis. Conclusions. Attention to risk factors and the individualization of patient care, especially regarding immunosuppression management, is crucial for delivering more precise interventions to these individuals.
  • article 36 Citação(ões) na Scopus
    COVID-19-related hospital cost-outcome analysis: The impact of clinical and demographic factors
    (2021) MIETHKE-MORAIS, Anna; CASSENOTE, Alex; PIVA, Heloisa; TOKUNAGA, Eric; COBELLO, Vilson; GONCALVES, Fabio Augusto Rodrigues; LOBO, Renata dos Santos; TRINDADE, Evelinda; D'ALBUQUERQUE, Luiz Augusto Carneiro; HADDAD, Luciana
    Introduction: Although patients' clinical conditions have been shown to be associated with coronavirus disease (COVID-19) severity and outcome, their impact on hospital costs are not known. This economic evaluation of COVID-19 admissions aimed to assess direct and fixed hospital costs and describe their particularities in different clinical and demographic conditions and outcomes in the largest public hospital in Latin America, located in Sao Paulo, Brazil, where a whole institute was exclusively dedicated to COVID-19 patients in response to the pandemic. Methods: This is a partial economic evaluation performed from the hospital's perspective and is a prospective, observational cohort study to assess hospitalization costs of suspected and confirmed COVID-19 patients admitted between March 30 and June 30, 2020, to Hospital das Clinicas of the University of Sao Paulo Medical School (HCFMUSP) and followed until discharge, death, or external transfer. Micro- and macro-costing methodologies were used to describe and analyze the total cost associated with each patient's underlying medical conditions, itinerary and outcomes as well as the cost components of different hospital sectors. Results: The average cost of the 3254 admissions (51.7% of which involved intensive care unit stays) was US$12,637.42. The overhead cost was its main component. Sex, age and underlying hypertension (US$14,746.77), diabetes (US$15,002.12), obesity (US$18,941.55), chronic renal failure (US$15,377.84), and rheumatic (US$17,764.61), hematologic (US $15,908.25) and neurologic (US$15,257.95) diseases were associated with higher costs. Age strata >69 years, reverse transcription polymerase chain reaction (RT-PCR)-confirmed COVID-19, comorbidities, use of mechanical ventilation or dialysis, surgery and outcomes remained associated with higher costs. Conclusion: Knowledge of COVID-19 hospital costs can aid in the development of a comprehensive approach for decision-making and planning for future risk management. (C) 2021 Sociedade Brasileira de Infectologia.